Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.36 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | GGH | Q92820 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.35 |
| ▸ | BMP1 | P13497 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158281 | 1.00 | KMT2A (0.42) | KMT2AALOX15BLMPMP22MMP2 | |
| SCHEMBL7604126 | 0.88 | KMT2A (0.41) | KMT2AALOX15BLMPMP22MMP2 | |
| SCHEMBL2641029 | 0.85 | FOLH1 (0.52) | FOLH1RIMKLANAALAD2GGH | |
| SCHEMBL7762307 | 0.84 | KMT2A (0.44) | KMT2AALOX15BLMPMP22MMP2 | |
| SCHEMBL2248015 | 0.84 | KMT2A (0.44) | KMT2AALOX15BLMPMP22MMP2 | |
| SCHEMBL8520404 | 0.82 | TGFBR1 (0.38) | KMT2AALOX15BLMPMP22MMP2 | |
| SCHEMBL7050367 | 0.82 | NOD1 (0.47) | KMT2ANOD1 | |
| SCHEMBL19816805 | 0.82 | NOD1 (0.47) | KMT2ANOD1 | |
| SCHEMBL8633804 | 0.82 | KMT2A (0.47) | KMT2AALOX15BLMPMP22MMP2 | |
| SCHEMBL5155261 | 0.81 | ECE1 (0.42) | KMT2ACA2CA1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105440222-B | A kind of polyaminoacid nonionic macromolecules cross-linking agent and preparation method thereof | 宁波大学 | 2018-10-02 | — | — | CN | claimed |
| US-20190106463-A1 | ENGINEERED POLYPEPTIDES FOR ANTIGEN DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-04-11 | — | — | US | disclosed |
| WO-2017165636-A1 | ENGINEERED POLYPEPTIDES FOR ANTIGEN DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20100145018-A1 | Lipid-Polymer-Conjugates | ASTELLAS PHARMA EUROPE BV (NL) | 2010-06-10 | — | — | US | disclosed |
| US-20070098664-A1 | Cosmetic application of rod-coil copolymers | L'OREAL (FR) | 2007-05-03 | — | — | US | disclosed |
| EP-1392756-B1 | LIPID-POLYMER-CONJUGATES | ASTELLAS PHARMA EUROP B V (NL) | 2007-02-14 | — | — | EP | disclosed |
| US-20040254352-A1 | Lipid-polymer-conjugates | YAMANOUCHI EUROPE B.V. (NL) | 2004-12-16 | — | — | US | disclosed |
| US-20040241222-A1 | Lipid-polymer-conjugates compositions | ASTELLAS PHARMA EUROPE B.V. (NL) | 2004-12-02 | — | — | US | disclosed |
| EP-1392756-A2 | LIPID-POLYMER-CONJUGATES | Yamanouchi Europe B.V. (NL) | 2004-03-03 | — | — | EP | disclosed |
| EP-1392755-A1 | LIPID-POLYMER-CONJUGATES COMPOSITIONS | YAMANOUCHI EUROPE B.V. (NL) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098952-A1 | LIPID-POLYMER-CONJUGATES COMPOSITIONS | YAMANOUCHI EUROPE B.V. (NL) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002098951-A2 | LIPID-POLYMER-CONJUGATES | YAMANOUCHI EUROPE B.V. (NL) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145018-A1 | Lipid-Polymer-Conjugates | PARG, GLUL, PHOSPHO1 | KMT2A 212/4885ALOX15 1425/4885BLM 1503/4885 |
| US-20040254352-A1 | Lipid-polymer-conjugates | PARG, GLUL, PARN | KMT2A 234/4885ALOX15 1412/4885BLM 1464/4885 |
| US-20040241222-A1 | Lipid-polymer-conjugates compositions | PHOSPHO1, PARG, GLUL | KMT2A 500/4885ALOX15 2551/4885BLM 1244/4885 |
| US-20070098664-A1 | Cosmetic application of rod-coil copolymers | COIL, CRYAB, CRYZ | KMT2A 4564/4885ALOX15 3984/4885BLM 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.